Companies/Prostatype Genomics AB
Follow

Prostatype Genomics AB

Nasdaq First North GM Stockholm (Sweden)

Prostatype Genomics manufactures, markets and sells the prognostic gene test Prostatype. By giving a assessment of the aggressiveness of the prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions.
Go to market

Sector:
HEALTH CARE
>
Health Care Equipment & Services
Healthcare
Media
Showing 3 of 4
View all
www.prostatypegenomics.com
Rights issue
Price
2.90 SEK
Subscription period
06 Jul - 20 Jul 2022
View Details
Top
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.
Show archived

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
PROGEN
SE0014684569
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Prostatype Genomics AB with ticker PROGEN
Status
Active
Amount of instruments
13 186 870
Currency
SEK
First trading date
03 Nov 2020
Directed issue
Sign in to buy
Exercise
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
PROGEN TO2
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Prostatype Genomics AB with ticker PROGEN TO2
Status
Inactive
Amount of instruments
—
Currency
SEK
First trading date
—
Terms
One (1) warrant TO2 entitles the holder to subscribe for one (1) new share for SEK 2.90 during the period March 9, 2023 - March 30, 2023.
Exercise
Sign in to buy
Type
Ticker
ISIN
Market
SHARE
PROGEN
SE0014684569
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in Prostatype Genomics AB with ticker PROGEN
Status
Active
Amount of instruments
13 186 870
Currency
SEK
First trading date
03 Nov 2020
Directed issue
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
PROGEN TO1
SE0014956462
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Prostatype Genomics AB with ticker PROGEN TO1
Status
Archived
Amount of instruments
3 885 320
Currency
SEK
Trading period
03 Nov 2020 - 15 Feb 2022
Terms
One (1) warrant entitles the holder to subscribe for one (1) new share in the Company for SEK 10.90 during the subscription period from January 27, 2022 until February 17, 2022.
Update (27.01.2022): Start of subscription period for warrants TO1.
Exercise
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
PROGEN TO2
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in Prostatype Genomics AB with ticker PROGEN TO2
Status
Inactive
Amount of instruments
—
Currency
SEK
First trading date
—
Terms
One (1) warrant TO2 entitles the holder to subscribe for one (1) new share for SEK 2.90 during the period March 9, 2023 - March 30, 2023.
Exercise
Sign in to buy
People
Fredrik Persson
CEO
Anders Lundberg
Chairman of the board
Michael Häggman
Board member
Karlheinz Schmelig
Board member
Håkan Englund
Board member
Christoph Petry
Board member
Company Details
Sector
HEALTH CARE
Website
Address
Industrivägen 19
Zip code
171 48
City/district
Solna
Country
Sweden (SE)
Phones
Email
[email protected]
Registration number
556726-0285
LEI code
549300JO6MPCGPVHVU91
First trade date
03 Nov 2020
Registration date
12 Mar 2007
Short name
Prostatype Genomics

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More